Exercise versus fixed-dose combination therapy for cardiovascular risk factors control and atherosclerotic disease prevention: a network meta-analysis protocol

Diana P Pozuelo-Carrascosa,1,2,3 Iván Cavero-Redondo,1,4 Rubén Fernández Rodríguez,5 Carlos Pascual Morena,1 Irene Sequí-Domínguez,1 Vicente Martínez-Vizcaíno1,6

ABSTRACT

Introduction Despite the consistent evidence of the benefits of physical activity on preventing atherosclerotic cardiovascular diseases (ASCVD) and some cardiovascular risk factors, such as hypertension and dyslipidaemia, the prescription of drugs remains the most widely used approach to prevent ASCVD in clinical settings. The purpose of this study protocol is to provide a meta-synthesis methodology for comparing the effect of fixed-dose combination therapy and physical exercise on controlling cardiovascular risk factors and preventing ASCVD.

Methods and analysis This protocol follows the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols and the recommendations of the Cochrane Collaboration Handbook. We plan to conduct a computerised search in Medline, Web of Science, Embase, Cochrane Database of Systematic Reviews and SPORTDiscus from inception to May 2020 for studies testing the effectiveness of physical exercise or fixed-dose combination drug therapy in preventing ASCVD, all-cause and cardiovascular mortality and controlling some cardiovascular risk factors (hypertension and dyslipidaemia). Since performing network meta-analyses (NMA) is a statistical approach that allows direct and indirect comparisons of interventions, where sufficient studies are included, we plan to perform the following NMA comparing the effect of fixed-dose combination therapy and physical exercise interventions on (1) improving lipid profile, (2) reducing blood pressure, (3) preventing cardiovascular events and all-cause and cardiovascular mortality and (4) improving compliance with the therapeutic strategy and reducing adverse events.

Ethics and dissemination Ethical approval will not be needed because data included in the NMA will be extracted from published trials that meet accepted ethical standards. The results will be published in academic peer-reviewed journals, and the evidence gathered by this project could be included in the preventive cardiovascular disease guidelines.

PROSPERO registration number CRD42019122794.

INTRODUCTION

Atherosclerotic cardiovascular diseases (ASCVD) is a term that encompasses a group of disorders of the heart and blood vessels that are the principal cause of death worldwide, as evidenced by the fact that in 2015, ASCVD was responsible for more than 17 million deaths in the world.1 Furthermore, in most countries, these mortality figures are increasing, probably due to worldwide increases in population size and ageing.2 Among ASCVD,
Objective

The main objectives of this study protocol are to provide standardised and clear procedures for a set of NMAs (or meta-analysis if NMAs will be not possible) aimed at synthesising all the available evidence about the independent effects of physical exercise and fixed-dose combination therapy interventions, as well as the pooled effect differences between these two interventions, on (1) preventing ASCVD events (coronary heart disease, stroke and peripheral artery disease), all-cause mortality and cardiovascular mortality; (2) improving lipid levels; (3) decreasing blood pressure and (4) reducing their adverse events and improving adherence rates.

Methods and design

The present NMA protocol was planned, conducted and reported according to the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) and The Cochrane Handbook for Systematic Reviews of Interventions.11–14

Eligibility criteria

Type of studies

Randomised controlled trials (RCTs) aimed to assess the effectiveness of physical exercise interventions or fixed-dose combination drug therapy in controlling and improving some cardiovascular risk factors (hypercholesterolaemia and/or high blood pressure). In addition, prospective and cohort studies will be included in the study aimed to compare the effectiveness of physical exercise with fixed-dose combination therapy in preventing ASCVD events (coronary heart disease, stroke and peripheral artery disease) and all-cause and cardiovascular mortality due to the nature of these outcomes.

Types of participants

We will include primary and/or secondary atherosclerosis prevention RCTs (in addition to prospective cohort studies on mortality and ACVD event outcomes) written in English or Spanish, including high-risk adults treated with fixed-dose combination therapy and/or physical exercise interventions.

Studies in children or adolescents and/or those involving treatments other than exercise or fixed-dose combination therapy in the intervention group will be excluded.

Type of interventions

We will consider for inclusion RCTs that report any type of supervised and structured exercise interventions (aerobic, resistance, anaerobic, high-intensity training, balance, stretching, Tai Chi, Pilates or yoga) or a combination (eg, aerobic+balance), with a frequency higher than one session/week and with a programme duration of at least 4 weeks. We will exclude studies that combine physical exercise with other interventions (eg, nutritional intervention) when data cannot be separately extracted.

Predictably, in the cohort studies included to assess the effectiveness of physical exercise and fixed-dose combination therapy in preventing ACVD and mortality, it is possible that physical exercise will not be supervised and structured interventions, and only data about self-reported physical activity amounts and the type of exercise realised will be reported.

Regarding pharmacological treatment, we will consider all RCTs aimed at assessing the effectiveness of fixed-dose combination therapy used to treat or prevent the following pathologies: ASCVD events (ischaemic heart disease, stroke and peripheral artery disease), hypercholesterolaemia or high blood pressure. The polypill represents a therapeutic strategy that usually combines single-pill blood pressure-lowering drugs and high-potency statins with or without aspirin.15

Type of outcome measures

We plan to conduct four NMAs in which the primary outcomes will be the following:

- Outcomes about the blood lipid profile (low-density lipoprotein cholesterol (LDL-c), triglycerides, total cholesterol, high-density lipoprotein cholesterol (HDLC-c)) for the first NMA.
- Outcomes about blood pressure (systolic blood pressure and diastolic blood pressure) for the second NMA.
- Ischaemic heart disease, stroke and peripheral artery disease events, all-cause mortality, cardiovascular mortality and total cardiovascular events for the third NMA.
NMA. Apart from individual outcomes (eg, incidence of coronary heart disease), we will also consider composite cardiovascular outcomes (eg, 10-year Framingham cardiovascular disease risk reduction).

Finally, in the fourth NMA, the primary outcomes will be adverse events and adherence.

**Search strategy**

The electronic search will be conducted by DPP-C and IC-R, and differences will be solved by discussion with a third reviewer (VM-V). We will conduct the searches using the following electronic databases: Medline (via PubMed), Web of Science, Embase, Cochrane Database of Systematic Reviews and SPORTDiscus from inception to May 2020.

For each NMA, the search will be based on the PICO strategy (Patients/Population, Intervention, Comparison and Outcomes) and will include terms related to physical exercise intervention and fixed-dose combination therapy, cardiovascular risk factors (hypercholesterolaemia and high blood pressure), ASCVD events (ischaemic heart disease, stroke and peripheral artery disease), mortality, adverse events and adherence, depending on each NMA (online supplementary file 1).

The search strategy will be adapted for each NMA and database. Moreover, we will explore the reference lists from the retrieved articles to search for further relevant studies that potentially meet the inclusion criteria. There will be no restrictions by publication year or country of the study.

**Study selection process and data extraction**

Two reviewers will independently screen titles and abstracts after removing duplicate retrieved records. Reviewers will examine the full text articles applying the inclusion/exclusion criteria. Inconsistencies in study selection will be solved by consensus. A third reviewer (VM-V) will be consulted when disagreements persist. A flow chart will display the study selection process and the reasons for exclusions (figure 1). When several studies provide data from the same sample, we will include the one containing the most detailed information or providing the largest sample size. If relevant data are missing, we will send mail to corresponding authors requesting them.

Equally, for each NMA, two reviewers will extract the following study characteristics, which are summarised in tables 1–4: (1) the first author; (2) year of publication; (3) country; (4) length of follow-up; (5) characteristics of participants (age, sample size, sex); (6) outcomes: levels of HDL-c, LDL-c, total cholesterol, triglycerides, blood pressure, ASCVD events (ischaemic heart disease, stroke and peripheral artery disease), mortality (total and cardiovascular mortality), adverse events and data regarding adherence and (7) characteristics of treatment and control groups: type of treatment (drug name, composition, dose) and/or type of exercise, intensity, duration and frequency.

Assessment of risk of bias

Two authors will independently assess the included full-text RCTs for methodological quality using the risk-of-bias assessment tool from the Cochrane Collaboration.16 This tool includes the following domains: (1) bias arising from the randomisation process, (2) bias due to deviations from intended interventions, (3) bias due to missing outcome data, (4) bias in measurement of the outcome and (5) bias in selection of the reported results. Each domain will be assessed as ‘low’, ‘high’ or ‘some concerns’ risk of bias, so that overall bias will be considered ‘low risk of bias’ when the paper is classified as ‘low risk’ in all domains, as ‘some concerns’ when there is at least one domain with rating of ‘some concern’ and as ‘high risk of bias’ if there is at least one domain with a ‘high risk’, or when there are several domains with ‘some concerns’ rating.

The validated Newcastle-Ottawa Scale for cohort studies will be used to assess the quality of the studies assessing the effectiveness of physical activity on the incidence of ACVD events and mortality.17 This scale assigns four points for quality of selection, two points for comparability and three points for quality of outcome and adequacy of follow-up, with a maximal score of nine points.

The agreement rate between reviewers will be reported by calculating kappa statistics. A third researcher (VM-V) will assess inconsistencies

Grading the quality evidence

The Grading of Recommendations, Assessment, Development and Evaluation tool will be used to evaluate the quality of evidence.18 For each outcome variable, an evidence value will be assigned (high, moderate, low or very low) depending on the study’s design, risk of bias, inconsistency, indirect evidence, imprecision and publication bias.
Table 1  Characteristics of studies included in the network meta-analysis

| Study characteristics | Population characteristics | Outcomes | Intervention/control groups |
|-----------------------|---------------------------|----------|-----------------------------|
| Authors/year, Country | Follow-up (years (mean±SD))/sample size (n (% male)) | HDL-c, LDL-c, Triglycerides, Total cholesterol | IG: Dose Drug Type of exercise Frequency Duration Intensity |
|                       |                           |          | CG: Dose Drug Type of exercise Frequency Duration Intensity |

CG, control group; HDL-c, high-density lipoprotein cholesterol; IG, intervention group; LDL-c, low-density lipoprotein cholesterol.

Table 2  Characteristics of studies included in the network meta-analysis

| Study characteristics | Population characteristics | Outcomes | Intervention/control groups |
|-----------------------|---------------------------|----------|-----------------------------|
| Authors/year, Country | Follow-up (years (mean±SD))/sample size (n (% male)) | SBP, DBP | IG: Dose Drug Type of exercise Frequency Duration Intensity |
|                       |                           |          | CG: Dose Drug Type of exercise Frequency Duration Intensity |

CG, control group; DBP, diastolic blood pressure; IG, intervention group; SBP, systolic blood pressure.
### Table 3  Characteristics of studies included in the network meta-analysis

| Study characteristics | Population characteristics | Outcomes | Intervention/control groups |
|-----------------------|---------------------------|----------|----------------------------|
| Authors/year          | Country                   | Follow-up| Age (years (mean±SD))/sample size (n (% male)) | Ischaemic heart disease | Stroke | Peripheral artery disease | Mortality Total: CVD: |
|                       |                           |          | IG: Dose Drug Type of exercise | CG: Dose Drug Type of exercise |
|                       |                           |          | Frequency Duration Intensity | Frequency Duration Intensity |

CG, control group; CVD, cardiovascular diseases; IG, intervention group.

### Table 4  Characteristics of studies included in the network meta-analysis

| Study characteristics | Population characteristics | Outcomes | Intervention/control groups |
|-----------------------|---------------------------|----------|----------------------------|
| Authors/year          | Country                   | Follow-up| Age (years (mean±SD))/sample size (n (% male)) | Adverse events | Adherence | IG: Dose Drug Type of exercise | Frequency Duration Intensity |
|                       |                           |          | CG: Dose Drug Type of exercise | Frequency Duration Intensity |

CG, control group; IG, intervention group.
Data synthesis

We will conduct the NMAs according to the PRISMA-NMA statement, distinguishing the following phases:

First, by using a network graph for each outcome, we will perform direct comparisons between the intervention group (physical exercise or fixed-dose combination therapy) and the control group. For that, we will perform random effects pairwise meta-analyses in terms of the post intervention scores or the changes from baseline values of the different treatment options for each outcome. For this, the standardised mean difference (SMD) and the risk ratio (RR) (for continuous and dichotomous variables, respectively) from preintervention to post intervention and between groups (intervention vs control) in each study will be calculated and pooled using the random-effect DerSimonian-Laird method. Second, in cases where it is possible to carry out an NMA, it will be used to conduct simultaneous comparisons of several interventions creating a connected network using the totality of the available evidence (direct and indirect comparisons).

For each outcome, we will report the mean treatment effect with its 95% credible CI of all interventions relative to the control and other interventions and the estimated common network-specific heterogeneity parameter. The statistical heterogeneity will be examined using the I² statistic, and according to its values, the heterogeneity will be considered not important (0%-40%), moderate (30%-60%), substantial (50%-90%) and considerable (75%-100%). Furthermore, the τ² statistic will be calculated using the following values for its interpretation: 0.04 as a low, 0.14 as a moderate and 0.40 as a substantial degree of clinical relevance of heterogeneity. These results will be displayed by creating both forest plots and a league table. In addition, we will calculate the relative ranking of the different treatments for each outcome using the distribution of the ranking probabilities and the surface under the cumulative ranking (SUCRA). SUCRA represents an inversely scaled average rank of the intervention, with a numerical value between 0 and 1. The best treatment would obtain a value close to 1, and the worst intervention would obtain a value close to 0.

Consistency will be assessed using the Wald test, and we will use sidesplitting as an additional assessment of inconsistency. For the transitivity assessment, we will check that all participants in the studies included in the NMA had similar baseline important clinical and methodological strengths and limitations.

The small study effect and publication bias will be analysed, and a network funnel plot will be used to visually scrutinise the criterion of symmetry. All analyses will be conducted with Stata V.15.0 (Stata).

DISCUSSION

The benefits of regular physical activity to prevent and treat ASCVD have been extensively described in the scientific literature. This is because physical activity prevents and helps treat many atherosclerotic risk-related factors, such as insulin resistance, glucose intolerance, elevated blood pressure, elevated triglyceride levels, high LDL-c concentrations, low levels of HDL-c and obesity.

Pharmacological interventions are commonly used to improve cardiovascular risk factor levels and prevent ASCVD, although an active lifestyle and a healthy diet are considered the first line in primary prevention, as several guidelines suggest. In fact, a recent NMA found a modest but consistent reduction in systolic blood pressure through structured exercise interventions (aerobic, resistance and combined) of any frequency, duration or intensity; this study reported, in patients with hypertension, effects for exercise interventions similar to those of antihypertensive medication, although we should consider that the characteristics of patients included in the studies differed substantially. In addition, other studies have shown improvements in other cardiometabolic risk factors, such as triglycerides, HDL-c, fasting glucose, HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) and/or HbA1c (Hemoglobin A1c), associated with exercise practice.

Thus, physical activity seems to be an attractive alternative to pharmacological intervention as a first-line treatment in managing cardiovascular risk factors such as hypertension and dyslipidaemia due to its comparatively less frequent and severe side effects; nevertheless, because of the low level of long-term adherence to exercise, more research addressing this issue is needed.

Among the pharmacological strategies, the fixed-dose combination has emerged as a promising strategy, although its effectiveness in the prevention of all-cause mortality or ASCVD events is uncertain. In fact, some authors recommend not using the polypill in isolation but as a part of a comprehensive ASCVD prevention strategy that includes, among other components, physical activity.

Given the importance of controlling cardiovascular risk factors and the multiple health benefits of physical activity, a more detailed and comprehensive review on the effects of exercise on cardiovascular health risk factors seems necessary. This protocol provides clear and structured procedures for maximising the extraction of relevant information and provides summarised information. The results of these studies could influence evidence-based decisions for patients and practitioners and may potentially be included in guidelines for the management of some cardiovascular risk factors, such as blood lipids and overall cardiovascular risk.

Strengths and limitations

The main anticipated limitations are inherent to meta-analyses, such as limited or incoherent information from studies, high heterogeneity and risk-of-bias assessments; thus, conclusions should be interpreted cautiously and with consideration of these limiting factors. To reduce and control these limitations, this work will follow PRISMA guidelines and
the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions.14

ETHICS AND DISSEMINATION

Ethical approval will not be needed because data included in the NMA will be extracted from published trials that meet accepted ethical standards, and there will be no concerns about privacy. With the aim of disseminating the evidence obtained, the results will be published in a peer-reviewed international journal to improve clinical practices with scientific evidence. The evidence obtained could be included in guidelines to prevent cardiovascular diseases.

Patients and practitioner’s involvement

The prevention of ASCVDs is a major concern for both clinicians and patients. The results of these studies will potentially be useful for providing the best available evidence regarding the comparative effect of a polypill and exercise on preventing ASCVD events and all-cause mortality, but because our design is a secondary analysis of published studies, we felt that clinician and patient involvement was not required at this time. However, to reach the highest impact, as noted above, we will widely disseminate our findings in scientific symposiums and journals, as well as via social networks and the media.

Author affiliations

1 Social and Health Care Research Center, Universidad de Castilla-La Mancha, Cuenca, Spain
2 Facultad de Fisioterapia y Enfermería, Universidad de Castilla-La Mancha, Toledo, Spain
3 Multidisciplinary Research Group in Care (IMCU), Universidad de Castilla-La Mancha, Toledo, Spain
4 Universidad Politécnica y Artística del Paraguay, Asunción, Paraguay
5 Movi-fitness S.L, Universidad de Castilla-La Mancha—Campus de Cuenca, Cuenca, Cuenca, Spain
6 Faculty of Health Sciences, Universidad Autónoma de Chile—Sede Talca, Talca, Chile

Contributors Conceptualisation: DPP-C. Data curation: DPP-C, VM-V and CPM. Formal analysis: DPP-C, IC-R and VM-V. Funding acquisition and supervision: VM-V. Investigation and methodology: DPP-C and IC-R. Writing—original draft: VM-V and DPP-C. Writing—review and editing: RFR, IS-D and CPM.

Funding This study was funded by the Consejería de Educación, Cultura y Deportes—Junta de Comunidades de Castilla-La Mancha and FEDER funds (SBPLY/17/180501/000533). Diana P. Pozuelo Carrascosa is contracted by FEDER funds (2019/7375).

Disclaimer This article was edited for proper English language, grammar, punctuation, spelling and overall style by one or more of the highly qualified native English-speaking editors at Springer Nature Author Services.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1 Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 2017;70:1–25.
2 Mendis S. Global progress in prevention of cardiovascular disease. Cardiovasc Diagn Ther 2017;7:522–8.
3 Mendis S, Puska P, Norving B, et al. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization, 2011.
4 F Piepoli M. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Int J Behav Med 2017;24:321–49.
5 Salanti G, Farzaifar F, Jafari E, et al. Cardiovascular disease prevention using fixed dose phosphorotherapy in Iran: updated meta-analyses and mortality estimation. Arch Iran Med 2012;15:531–7.
6 Carey KM, Comee MR, Donovan JL, et al. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. Ann Pharmacother 2012;46:688–95.
7 Bahiru E, de Cates AN, Farr MR, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev 2017;3:CD009868.
8 Webser R, Patel A, Selaik V, et al. Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: a prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol 2016;205:147–56.
9 Fiuza-Luces C, Green S. Cochrane Handbook for systematic reviews of interventions version 5.1. 0. The cochrane collaboration, 2011.
10 Lave CJ, Arena R, Swift DL, et al. Exercise and the cardiovascular system: clinical science and cardiovascular outcomes. Circ Res 2015;117:207–19.
11 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
12 Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
13 Chaimani A, Caldwell DM, Li T, et al. Additional considerations are required when preparing a protocol for a systematic review with multiple interventions. J Clin Epidemiol 2017;83:65–74.
14 Higgins JP, Green S. Cochrane Handbook for systematic reviews of interventions version 5.1. 0. The cochrane collaboration, 2011.
15 Huffman MD, Salam A, Patel A. Implementation strategies for cardiovascular Polypills. JAMA 2019. doi:10.1001/jama.2019.18102. [Epub ahead of print: 25 Nov 2019].
16 Higgins J, Sterne J, Savovíc J, et al. A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev 2016;10:29–31.
17 Wells G, Shea B, O’Connor D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
18 Schuemann HBJ, Guyatt G, Caldwell DM. Grade Handbook for grading quality of evidence and strength of recommendations. The grade Working group, 2013. Available: guidelinedevelopment.org/ handbook.
19 Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777–84.
20 Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163–71.
21 DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007;28:105–14.
22 Cipriani A, Higgins JPT, Geddes JR, et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013;159:130–7.
23 Riley RD, Higgins JPT, Deeks J. Interpretation of random effects network meta-analyses. BMJ 2011;343.d5210.
24 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.

Pozuelo-Carrascosa DP, et al. BMJ Open 2020;10:e036734. doi:10.1136/bmjopen-2019-036734
Pozuelo-Carrascosa DP, et al. BMJ Open 2020;10:e036734. doi:10.1136/bmjopen-2019-036734

25 Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.

26 Baker SG, Kramer BS. The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol 2002;2:13.

27 Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012;3:80-97.

28 Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on clinical cardiology (Subcommittee on exercise, rehabilitation, and prevention) and the Council on nutrition, physical activity, and metabolism (Subcommittee on physical activity). Circulation 2003;107:3109–16.

29 Duerden M, O’Flynn N, Qureshi N. Cardiovascular risk assessment and lipid modification: NICE guideline. Br J Gen Pract 2015;65:378–80.

30 Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;74:1376–414.

31 Naci H, Salcher-Konrad M, Dias S, et al. How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 randomised controlled trials assessing exercise and medication effects on systolic blood pressure. Br J Sports Med 2019;53:859–69.

32 Lin X, Zhang X, Guo J, et al. Effects of exercise training on cardiorespiratory fitness and biomarkers of cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2015;4:e002014.

33 Leon AS, Rice T, Mandel S, et al. Blood lipid response to 20 weeks of supervised exercise in a large biracial population: the heritage family study. Metabolism 2000;49:513–20.

34 Noone C, Dwyer CP, Murphy J, et al. Comparative effectiveness of physical activity interventions and anti-hypertensive pharmacological interventions in reducing blood pressure in people with hypertension: protocol for a systematic review and network meta-analysis. Syst Rev 2018;7:128.

35 Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.